{"id":33771,"date":"2025-10-21T17:16:19","date_gmt":"2025-10-21T11:46:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33771"},"modified":"2025-10-21T17:16:21","modified_gmt":"2025-10-21T11:46:21","slug":"pharma-news-for-roche-astrazeneca-replimune","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune","title":{"rendered":"FDA Approves Genentech\u2019s GAZYVA for Lupus Nephritis; Glaukos\u2019 EPIOXA Wins FDA Approval for Keratoconus Treatment; FDA Accepts Replimune\u2019s RP1 BLA Resubmission for Advanced Melanoma; Cogent\u2019s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN; Amgen\u2019s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a140ecb91c4f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a140ecb91c4f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\/#FDA_Approves_Genentechs_GAZYVA_for_Lupus_Nephritis\" >FDA Approves Genentech\u2019s GAZYVA for Lupus Nephritis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\/#Glaukos_EPIOXA_Wins_FDA_Approval_for_Keratoconus_Treatment\" >Glaukos\u2019 EPIOXA Wins FDA Approval for Keratoconus Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\/#FDA_Accepts_Replimunes_RP1_BLA_Resubmission_for_Advanced_Melanoma\" >FDA Accepts Replimune\u2019s RP1 BLA Resubmission for Advanced Melanoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\/#Cogents_Bezuclastinib_Earns_FDA_Breakthrough_Therapy_for_SM-AHN\" >Cogent\u2019s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\/#Amgens_TEZSPIRE_Gets_FDA_Nod_for_Chronic_Rhinosinusitis_with_Nasal_Polyps\" >Amgen\u2019s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-genentech-s-gazyva-for-lupus-nephritis\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Genentechs_GAZYVA_for_Lupus_Nephritis\"><\/span>FDA Approves Genentech\u2019s GAZYVA for Lupus Nephritis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Genentech<\/strong>, a member of the <strong>Roche Group<\/strong>, announced that the FDA has approved <strong>GAZYVA (obinutuzumab)<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\">treatment of adult patients with <strong>active lupus nephritis (LN)<\/strong><\/a><strong> <\/strong>receiving standard therapy. The approval is supported by data from the <strong>Phase II NOBILITY<\/strong> and <strong>Phase III REGENCY<\/strong> studies, where GAZYVA demonstrated superiority over standard therapy alone, becoming the <strong>first anti-CD20 monoclonal antibody<\/strong> to show a complete renal response benefit in a randomized Phase III LN trial.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s approval of GAZYVA offers renewed hope for people with lupus nephritis and their loved ones, as it provides an important new treatment option that has the potential to prevent long-term complications, including kidney failure,\u201d said <\/em><strong><em>Louise Vetter<\/em><\/strong><em>, President and CEO of the Lupus Foundation of America.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In the REGENCY study, nearly <strong>46.4% of patients<\/strong> receiving GAZYVA with standard therapy achieved a <strong>complete renal response<\/strong>, compared to 33.1% with standard therapy alone. These results were accompanied by improvements in key disease markers, including complement levels and proteinuria, and reduced corticosteroid use. The safety profile of GAZYVA remained consistent with its known use in hematology-oncology settings.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPeople with lupus nephritis who achieve a complete renal response are more likely to experience preserved kidney function and delay, or even prevention, of progression to end-stage kidney disease,\u201d said <\/em><strong><em>Levi Garraway, M.D., Ph.D.<\/em><\/strong><em>, Chief Medical Officer and Head of Global Product Development at Genentech. \u201cThis approval marks a significant step toward a potential new standard of care.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Lupus nephritis affects over <strong>1.7 million people globally<\/strong>, predominantly <strong>women of color and of childbearing age<\/strong>. Up to one-third of untreated patients may progress to end-stage kidney disease. GAZYVA offers a more convenient dosing regimen, following four initial doses in the first year, it can be administered <strong>twice yearly<\/strong> with an <strong>optional 90-minute infusion<\/strong> after the first dose. The therapy was granted <strong>Breakthrough Therapy Designation<\/strong> in 2019 and is also under regulatory review in Europe.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-glaukos-epioxa-wins-fda-approval-for-keratoconus-treatment\"><span class=\"ez-toc-section\" id=\"Glaukos_EPIOXA_Wins_FDA_Approval_for_Keratoconus_Treatment\"><\/span>Glaukos\u2019 EPIOXA Wins FDA Approval for Keratoconus Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has approved <strong>EPIOXA<\/strong> (EPIOXA HD \/ EPIOXA), developed by <strong>Glaukos Corporation<\/strong>, as the <strong>first and only incision-free, topical drug therapy<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/keratoconus-market\"><strong>keratoconus<\/strong><\/a>. This groundbreaking advancement introduces a new standard of care for a rare, sight-threatening condition that has long been underdiagnosed and undertreated. EPIOXA is designed to eliminate the need for epithelium removal during corneal cross-linking, offering a <strong>less invasive, more comfortable alternative<\/strong> to existing therapies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of EPIOXA ushers in a new standard-of-care for patients suffering from keratoconus,\u201d said <\/em><strong><em>Thomas Burns<\/em><\/strong><em>, Glaukos Chairman and CEO. \u201cEPIOXA is designed to significantly improve patient comfort and minimize recovery time, representing a game-changing new treatment. This marks a major milestone in our mission to improve access to sight-saving therapies.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval is based on data from <strong>two Phase III pivotal trials<\/strong> involving more than 400 patients. Both trials met their primary efficacy endpoints and demonstrated strong safety and tolerability profiles. EPIOXA uses a <strong>dual-formulation, oxygen-enriched system activated by UV light<\/strong>, which enables the therapeutic effect without damaging the eye\u2019s surface.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cKeratoconus is underdiagnosed and often untreated due to the invasive nature of current options,\u201d said <\/em><strong><em>Dr. W. Barry Lee<\/em><\/strong><em>, corneal specialist and President of the Cornea Society. \u201cAn incision-free treatment like EPIOXA that preserves the epithelium can address key patient concerns around pain and recovery.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Glaukos plans to launch EPIOXA commercially in <strong>Q1 2026<\/strong>, alongside broad initiatives to improve patient awareness, access, and early diagnosis. These include <strong>co-pay assistance programs, patient education strategies, and screening campaigns<\/strong> to address the significant unmet needs in the keratoconus patient community.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-replimune-s-rp1-bla-resubmission-for-advanced-melanoma\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_Replimunes_RP1_BLA_Resubmission_for_Advanced_Melanoma\"><\/span>FDA Accepts Replimune\u2019s RP1 BLA Resubmission for Advanced Melanoma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Replimune Group, Inc.<\/strong> announced that the FDA has accepted its <strong>Biologics License Application (BLA) resubmission<\/strong> for <strong>RP1 in combination with nivolumab<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-melanoma-market\"><strong>advanced melanoma<\/strong><\/a> in patients who have progressed on prior <strong>anti-PD-1 therapy<\/strong>. The agency has set a <strong>PDUFA date of April 10, 2026<\/strong>, following a Class II resubmission timeline.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are pleased the agency has accepted the resubmission of our BLA for RP1,\u201d said <\/em><strong><em>Sushil Patel, Ph.D.<\/em><\/strong><em>, CEO of Replimune. \u201cRP1 plus nivolumab offers a strong risk-benefit profile where there are few options for patients with advanced melanoma. We look forward to working with the FDA to expedite the review process.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Replimune\u2019s resubmission follows months of engagement with the FDA to address feedback outlined in a <strong>Complete Response Letter (CRL)<\/strong> issued in July 2025. The updated submission includes <strong>additional data, analyses, and information<\/strong> intended to support the potential approval of RP1 as a treatment option in this high-need patient population.<\/p>\n\n\n\n<p>The company continues to advance its <strong>oncolytic immunotherapy platform<\/strong>, with RP1 representing a novel approach that combines direct tumor killing with immune activation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cogent-s-bezuclastinib-earns-fda-breakthrough-therapy-for-sm-ahn\"><span class=\"ez-toc-section\" id=\"Cogents_Bezuclastinib_Earns_FDA_Breakthrough_Therapy_for_SM-AHN\"><\/span>Cogent\u2019s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cogent Biosciences announced that the FDA has granted <strong>Breakthrough Therapy Designation<\/strong> to <strong>bezuclastinib<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-mastocytosis-market\"><strong>NonAdvanced Systemic Mastocytosis (NonAdvSM)<\/strong><\/a> in patients previously treated with avapritinib, as well as those with <strong>Smoldering Systemic Mastocytosis<\/strong>, both populations with no approved standard of care.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are excited to announce Breakthrough Therapy Designation for bezuclastinib, which highlights the FDA\u2019s recognition of the unmet need in NonAdvSM and the potential for this therapy to redefine treatment,\u201d said <\/em><strong><em>Andrew Robbins<\/em><\/strong><em>, President and CEO of Cogent Biosciences. \u201cWe had a productive pre-NDA meeting with the agency and are on track to submit our NDA by the end of 2025.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The designation was based on <strong>positive results from the Phase III SUMMIT trial<\/strong>, in which bezuclastinib met all primary and key secondary endpoints and demonstrated consistent benefit in high-need subgroups. Top-line data were shared in July 2025, and full results will be presented at an upcoming scientific conference later this year.<\/p>\n\n\n\n<p>Breakthrough Therapy Designation streamlines the path to approval by providing eligibility for <strong>Priority Review, rolling submissions<\/strong>, and increased FDA engagement. Cogent is preparing for a potential commercial launch, supported by this designation and the strong efficacy data from SUMMIT.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-amgen-s-tezspire-gets-fda-nod-for-chronic-rhinosinusitis-with-nasal-polyps\"><span class=\"ez-toc-section\" id=\"Amgens_TEZSPIRE_Gets_FDA_Nod_for_Chronic_Rhinosinusitis_with_Nasal_Polyps\"><\/span>Amgen\u2019s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AstraZeneca and Amgen<\/strong> announced that the FDA has approved <strong>TEZSPIRE (tezepelumab)<\/strong> as an <strong>add-on maintenance treatment for adults and adolescents (12+) <\/strong>with <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-with-nasal-polyps-market\"><strong>chronic rhinosinusitis with nasal polyps (CRSwNP)<\/strong><\/a> who remain inadequately controlled. TEZSPIRE is now the first and only biologic targeting thymic stromal lymphopoietin (TSLP) approved for this indication, expanding its reach beyond severe asthma.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval introduces an innovative treatment option for patients, helping to break the cycle of debilitating symptoms, repeat surgeries, and steroid use,\u201d said <\/em><strong><em>Kenneth Mendez<\/em><\/strong><em>, President and CEO of the Asthma and Allergy Foundation of America.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval is supported by results from the <strong>Phase III WAYPOINT trial<\/strong>, where TEZSPIRE demonstrated significant reductions in <strong>nasal polyp size<\/strong>, <strong>need for surgery<\/strong>, and <strong>systemic corticosteroid use<\/strong>, with sustained symptom improvement. The safety profile was consistent with previous indications, with the most common adverse events being COVID-19, nasopharyngitis, and upper respiratory infections.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday\u2019s approval expands TEZSPIRE\u2019s use to another epithelial-driven inflammatory condition, reinforcing its unique mechanism of action across upper and lower airways,\u201d said <\/em><strong><em>Ruud Dobber<\/em><\/strong><em>, EVP, BioPharmaceuticals, AstraZeneca. Regulatory reviews are ongoing in the EU, China, Japan, and other markets following a recent <\/em><strong><em>positive CHMP opinion<\/em><\/strong><em>.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Genentech\u2019s GAZYVA for Lupus Nephritis Genentech, a member of the Roche Group, announced that the FDA has approved GAZYVA (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) receiving standard therapy. The approval is supported by data from the Phase II NOBILITY and Phase III REGENCY studies, where GAZYVA demonstrated [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33773,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20527,21820,22099,22098,204,704,2909,18713,18714,18715,6248,6250,17782,6249,420,639,22742],"industry":[17225],"therapeutic_areas":[17239,17227,17228,17244,17236],"class_list":["post-33771","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-advanced-melanoma","tag-advanced-melanoma-treatment","tag-chronic-rhinosinusitis-with-nasal-polyposis","tag-crswnp","tag-delveinsight","tag-fda","tag-keratoconus","tag-keratoconus-disease","tag-keratoconus-market","tag-keratoconus-treatment","tag-lupus-nephritis","tag-lupus-nephritis-market","tag-lupus-nephritis-pipeline","tag-lupus-nephritis-therapy","tag-news","tag-pharma-news","tag-systemic-mastocytosis","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-ophthalmology","therapeutic_areas-otolaryngology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Roche, AstraZeneca, Replimune<\/title>\n<meta name=\"description\" content=\"Genentech\u2019s GAZYVA; Glaukos\u2019 EPIOXA; Replimune\u2019s RP1; Cogent\u2019s Bezuclastinib; Amgen\u2019s TEZSPIRE\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Roche, AstraZeneca, Replimune\" \/>\n<meta property=\"og:description\" content=\"Genentech\u2019s GAZYVA; Glaukos\u2019 EPIOXA; Replimune\u2019s RP1; Cogent\u2019s Bezuclastinib; Amgen\u2019s TEZSPIRE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T11:46:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T11:46:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Roche, AstraZeneca, Replimune","description":"Genentech\u2019s GAZYVA; Glaukos\u2019 EPIOXA; Replimune\u2019s RP1; Cogent\u2019s Bezuclastinib; Amgen\u2019s TEZSPIRE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Roche, AstraZeneca, Replimune","og_description":"Genentech\u2019s GAZYVA; Glaukos\u2019 EPIOXA; Replimune\u2019s RP1; Cogent\u2019s Bezuclastinib; Amgen\u2019s TEZSPIRE","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-10-21T11:46:19+00:00","article_modified_time":"2025-10-21T11:46:21+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune","name":"Pharma News | Roche, AstraZeneca, Replimune","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature.webp","datePublished":"2025-10-21T11:46:19+00:00","dateModified":"2025-10-21T11:46:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Genentech\u2019s GAZYVA; Glaukos\u2019 EPIOXA; Replimune\u2019s RP1; Cogent\u2019s Bezuclastinib; Amgen\u2019s TEZSPIRE","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-astrazeneca-replimune#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-roche-astrazeneca-replimune"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/21170336\/21-10-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Advanced Melanoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">advanced melanoma treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic rhinosinusitis with nasal polyposis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRSwNP<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keratoconus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keratoconus disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keratoconus market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Keratoconus treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus nephritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus nephritis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Systemic Mastocytosis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Advanced Melanoma<\/span>","<span class=\"advgb-post-tax-term\">advanced melanoma treatment<\/span>","<span class=\"advgb-post-tax-term\">chronic rhinosinusitis with nasal polyposis<\/span>","<span class=\"advgb-post-tax-term\">CRSwNP<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Keratoconus<\/span>","<span class=\"advgb-post-tax-term\">Keratoconus disease<\/span>","<span class=\"advgb-post-tax-term\">Keratoconus market<\/span>","<span class=\"advgb-post-tax-term\">Keratoconus treatment<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis market<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Systemic Mastocytosis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 months ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Oct 21, 2025","modified":"Updated on Oct 21, 2025"},"absolute_dates_time":{"created":"Posted on Oct 21, 2025 5:16 pm","modified":"Updated on Oct 21, 2025 5:16 pm"},"featured_img_caption":"pharma-news-for-roche-astrazeneca-replimune ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33771"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33771\/revisions"}],"predecessor-version":[{"id":33772,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33771\/revisions\/33772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33773"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33771"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33771"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}